

1 Kinetic and Structural Characterization of a Flavin-Dependent 2 Putrescine *N*-Hydroxylase from *Acinetobacter baumannii*

3 Noah S. Lyons, Alexandra N. Bogner, John J. Tanner,* and Pablo Sobrado*

 Cite This: <https://doi.org/10.1021/acs.biochem.2c00493>

 Read Online


ACCESS |

 Metrics & More

 Article Recommendations

 Supporting Information

4 **ABSTRACT:** *Acinetobacter baumannii* is a Gram-negative oppor-
5 tunistic pathogen that causes nosocomial infections, especially
6 among immunocompromised individuals. The rise of multidrug
7 resistant strains of *A. baumannii* has limited the use of standard
8 antibiotics, highlighting a need for new drugs that exploit novel
9 mechanisms of pathogenicity. Disrupting iron acquisition by
10 inhibiting the biosynthesis of iron-chelating molecules (side-
11 rophores) secreted by the pathogen is a potential strategy for
12 developing new antibiotics. Here we investigated FbsI, an *N*-
13 hydroxylating monooxygenase involved in the biosynthesis of
14 fimsbactin A, the major siderophore produced by *A. baumannii*.
15 FbsI was characterized using steady-state and transient-state
16 kinetics, spectroscopy, X-ray crystallography, and small-angle X-ray scattering. FbsI was found to catalyze the *N*-hydroxylation of
17 the aliphatic diamines putrescine and cadaverine. Maximum coupling of the reductive and oxidative half-reactions occurs with
18 putrescine, suggesting it is the preferred (*in vivo*) substrate. FbsI uses both NADPH and NADH as the reducing cofactor with a
19 slight preference for NADPH. The crystal structure of FbsI complexed with NADP⁺ was determined at 2.2 Å resolution. The
20 structure exhibits the protein fold characteristic of Class B flavin-dependent monooxygenases. FbsI is most similar in 3D structure to
21 the cadaverine *N*-hydroxylases DesB and DfoA. Small-angle X-ray scattering shows that FbsI forms a tetramer in solution like the *N*-
22 hydroxylating monooxygenases of the SidA/IucD/PvdA family. A model of putrescine docked into the active site provides insight
23 into substrate recognition. A mechanism for the catalytic cycle is proposed where dehydration of the C4a-hydroxyflavin intermediate
24 is partially rate-limiting, and the hydroxylated putrescine product is released before NADP⁺.



25 **A** *Acinetobacter baumannii* is a Gram-negative opportunistic
26 pathogen that is responsible for nosocomial infections,
27 especially among immunocompromised individuals.¹ *A.*
28 *baumannii* is responsible for nearly 20% of intensive care
29 unit infections worldwide.² The bacteria is responsible for
30 infections in the bloodstream, respiratory system, urinary tract,
31 and soft tissues.³ Treatment of *A. baumannii* infections usually
32 consists of administration of β-lactam antibiotics; however, the
33 rise of multidrug resistant strains has limited the use of these
34 and other antibiotics against this bacterium.^{4,5}

35 One of the primary virulence factors associated with *A.*
36 *baumannii* infection are siderophores. Siderophores are ferric
37 iron-chelating compounds found in bacteria and fungi that
38 scavenge free iron from the host, which is then used for
39 microbial pathogen growth and virulence.⁶ *A. baumannii*
40 produces three structurally unique siderophores: acinetobac-
41 tin,⁷ baumannoferrin,⁸ and fimsbactin.⁹ Acinetobactin is the
42 best characterized siderophore and is present in nearly all
43 clinical isolates of *A. baumannii*. The baumannoferrins are
44 another siderophore released by *A. baumannii* and are the most
45 recently identified.⁸ The structure of baumannoferrin contains
46 a hydroxamate moiety and a large hydrophobic region, which
47 has been hypothesized to be associated with membrane

associated iron transport.¹⁰ The fimsbactins were first
48 identified in the clinical isolate *A. baumannii* ATCC 17978.⁹
49 Genomic analysis revealed a conserved biosynthetic operon
50 that encodes all the enzymes required for production of
51 hydroxamate-containing fimsbactins A–F.¹¹ Fimsbactin A is
52 the major siderophore produced and is directly implicated in
53 iron uptake, while B–F are believed to transport biosynthetic
54 intermediates involved in siderophore biosynthesis.⁹ The
55 production of three distinct classes of siderophores by *A.*
56 *baumannii* is not uncommon; the production of multiple
57 siderophores is associated with competition among pathogenic
58 microbes in nutrient-limiting conditions.^{12–15}

59 The fimsbactin A biosynthetic gene cluster encodes a
60 nonribosomal peptide synthase (NRPS), regulatory proteins,
61 and tailoring enzymes involved in the synthesis of the 2,3- 62

Received: August 25, 2022

Revised: October 7, 2022

63 dihydroxybenzoyl and *N*-acetyl-*N*-hydroxyputrescine moieties
 64 of the siderophore.⁹ One essential fimsbactin A biosynthetic
 65 enzyme, FbsI, has been annotated as a member of the SidA/
 66 IucD/PvdA family of monooxygenases and is thus predicted to
 67 be an NADPH-dependent *N*-hydroxylating monooxygenase
 68 (NMO) (EC 1.14.13.59).¹⁶ NMOs belong to the larger family
 69 of flavoproteins known as flavin-dependent monooxygenases
 70 (FMOs). FMOs are characterized by using a bound flavin
 71 prosthetic group, either FMN or FAD, to perform unique
 72 oxidation reactions following flavin reduction.¹⁷ Analysis of
 73 FbsI's amino acid sequence shows that it likely belongs to the
 74 Class B FMOs, which oxygenate small heteroatomic substrates
 75 and have two Rossmann-fold nucleotide binding domains—
 76 one for FAD/FMN and the other for the NADPH/NADH
 77 reducing cofactor. FbsI is the first of three enzymes involved in
 78 producing the hydroxamate moiety of fimsbactin A. FbsI is
 79 hypothesized to catalyze the *N*-hydroxylation of the aliphatic
 80 diamine putrescine into *N*-hydroxyputrescine (NHP) (Figure
 81 1A). *N*-Acetyl-NHP is then produced by the enzymes FbsJ and

at 37 °C with agitation at 250 rpm. For FbsI expression, 8 mL
 of overnight culture was used to inoculate 1 L of LB medium
 supplemented with kanamycin (50 μg/mL). Cultures were
 grown at 37 °C with agitation at 250 rpm until reaching an
 OD₆₀₀ of 0.8, where 0.5 mM isopropyl β-D-thiogalactopyrano-
 side (IPTG) was added to induce expression of FbsI. The
 temperature was lowered to 18 °C, and cultures were allowed
 to continue growing for 16 h. Cells were harvested by
 centrifugation at 4000g at 4 °C for 20 min and immediately
 stored at −70 °C.

Cells were resuspended (5 mL buffer/g cells) in Buffer A
 (25 mM HEPES, 300 mM NaCl, 20 mM imidazole, 10%
 glycerol, pH 7.5) supplemented with 1 mg/mL DNase, 1 mg/
 mL RNase, 1 mg/mL lysozyme, and 1 mM phenyl-
 methylsulfonyl fluoride (PMSF) and were continuously stirred
 at 4 °C for 30 min. The resuspended cells were lysed using
 sonication (Fisher Scientific Model 500) at 70% amplitude
 with cycles of 5 s on and 10 s off for 15 min. Cell debris was
 removed by centrifugation at 24 000g at 4 °C for 45 min. The
 clarified supernatant was loaded onto two in-tandem 5 mL
 HisTrap FF nickel IMAC columns equilibrated in three
 column volumes of Buffer A using an AKTA Start FPLC (GE
 Healthcare, Chicago, IL). Following protein loading, the
 columns were washed with approximately 50 mL of Wash
 Buffer (25 mM HEPES, 300 mM NaCl, 30 mM imidazole,
 10% glycerol, pH 7.5). FbsI was eluted with Buffer B (25 mM
 HEPES, 300 mM NaCl, 500 mM imidazole, 10% glycerol, pH
 7.5) using a linear gradient method. Yellow fractions, indicative
 of flavin-bound protein, were pooled together and dialyzed
 overnight into Buffer C (25 mM HEPES, 150 mM NaCl, 10%
 glycerol, 1 mM TCEP, pH 7.5). The dialyzed protein solution
 was concentrated using a 30 kDa centrifuge filter (Sigma-
 Aldrich, St. Louis, MO) and flash-frozen with liquid nitrogen
 before being stored at −70 °C. Purity of purified FbsI was
 evaluated using a 12% acrylamide SDS-PAGE analysis. The
 extinction coefficient for FbsI based on FAD concentration was
 determined as described previously.^{18,19}

Oxygen Consumption Assay. The consumption of
 oxygen by FbsI was measured using an oxygen electrode
 system (Hansatech, Norfolk, England). Steady-state kinetic
 parameters were determined by varying concentrations of
 substrate or NAD(P)H at a constant FbsI concentration (1
 μM). All assays were performed in 25 mM HEPES, pH 7.5, at
 a volume of 1 mL. Reaction components were continuously
 stirred and incubated for at least 30 s before initiating with
 NAD(P)H. All oxygen consumption assays were performed at
 room temperature (22 ± 2 °C). Data that showed a
 rectangular hyperbola were fit to eq 1, while data following
 substrate inhibition kinetics were fit to eq 2. The k_{cat} is the
 turnover number, $[S]$ is substrate concentration, $[E]$ is FbsI
 concentration, K_m is the Michaelis constant, and K_i is the
 inhibitor constant. All graph fitting analysis was performed
 using Kaleidagraph (Synergy Software, Reading, PA).

$$\frac{v_o}{[E]} = \frac{k_{\text{cat}}[S]}{K_m + [S]} \quad (1)$$

$$\frac{v_o}{[E]} = \frac{k_{\text{cat}}[S]}{K_m + [S] + \frac{[S]^2}{K_i}} \quad (2)$$

Product Formation Assay. The amount of hydroxylated
 amine products produced by FbsI was measured using a
 modified Csaky iodine oxidation assay.^{20–22} Reaction mixtures




Figure 1. (A) Reaction catalyzed by FbsI. (B) Structure of fimsbactin A, a primary siderophore produced by *A. baumannii*.

82 FbsK. Lastly, the *N*-acetyl-NHP moiety is added to the
 83 fimsbactin scaffold synthesized by the NRPS to produce
 84 functional fimsbactin A (Figure 1B). Knockout of the *fbsI* gene
 85 shows that the NHP moiety is not produced, suggesting its
 86 specific hydroxylation activity.⁹ In this work, we report the
 87 production of recombinant FbsI, the steady-state and transient-
 88 state kinetic characterization, the crystal structure of flavin-
 89 bound FbsI in complex with NADP⁺, and determination of the
 90 oligomeric structure in solution from small-angle X-ray
 91 scattering (SAXS).

92 ■ EXPERIMENTAL PROCEDURES

93 **Protein Production and Purification.** The FbsI gene
 94 subcloned into the pET28a expression vector was provided by
 95 Jinping Yang and Dr. Timothy Wenczewicz (Washington
 96 University in St. Louis). pET28a*fbsI* was transformed into
 97 OneShot BL21 (DE3) *Escherichia coli* cells purchased from
 98 Thermo Fisher Scientific (Waltham, MA). Overnight cultures
 99 were made by inoculating 50 mL of Luria–Bertani (LB)
 100 medium (10 g tryptone, 10 g sodium chloride, 5 g yeast extract
 101 per liter) supplemented with kanamycin (25 μg/mL) with a
 102 single colony of transformed *E. coli* cells and incubated for 12 h

161 consisted of 1 μM FbsI, 500 μM NADPH, varied substrate
162 concentrations (2.5–2000 μM), and 25 mM HEPES, pH 7.5,
163 in a final reaction volume of 120 μL . Standard solutions of
164 varied hydroxylamine concentrations (0–300 μM) were also
165 prepared. Reactions were initiated by addition of NADPH and
166 were allowed to incubate at room temperature, with
167 continuous shaking, for 5 min. Reactions were quenched by
168 the addition of 62.4 μL 2 N perchloric acid and centrifuged at
169 16 000 rpm for 2 min. A 47 μL aliquot of each reaction's
170 supernatant was transferred, in triplicate, to a 96-well plate.
171 Equal volumes (47 μL) of 10% w/v sodium acetate and 1% w/
172 v sulfanilic acid in 25% glacial acetic acid were added to the
173 reactions. 0.5% w/v iodine in 100% glacial acetic acid (19 μL)
174 was added, and reactions were incubated in the dark for 15
175 min. Color development was initiated by adding equal volumes
176 (19 μL) of 0.1 N sodium thiosulfate and 0.6% w/v 1-
177 naphthylamine. After shaking for 45 min, assay plates were
178 read at 562 nm using a Molecular Devices SpectraMax M5
179 plate reader.

180 **Detection of Products via Liquid Chromatography-
181 Mass Spectrometry (LC-MS) Analysis.** Reaction assays
182 (300 μL) consisting of 25 mM HEPES, pH 7.5, 25 μM
183 putrescine, 500 μM NADPH, and 1 μM FbsI were incubated
184 at room temperature. After 10 min, aliquots (50 μL) were
185 quenched with acetonitrile (100 μL) and chilled at $-20\text{ }^\circ\text{C}$ for
186 10 min. Following centrifugation at 16 000 rpm for 1 min, the
187 supernatant was added to 50 μL of 100 mM borate buffer, pH
188 8.0, followed by 20 μL of 10 mM fluorenylmethyloxycarbonyl
189 (Fmoc)-Cl dissolved in HPLC-grade methanol. Following
190 derivatization for 5 min, 20 μL of 100 mM 1-adamantylamine
191 (ADAM) dissolved in 1:1 0.2 mM HCl:MeCN was added to
192 the reaction and allowed to incubate at room temperature for
193 15 min to remove excess Fmoc-Cl. Samples were then analyzed
194 on a Waters Synapt Q-TOF mass spectrometer interfaced with
195 a Waters Acquity UPLC (Waters Corp, Milford Ma.) The
196 UPLC was operated at a flow rate of 0.2 mL/min, and 10 μL of
197 sample was injected onto a Waters Acquity BEH C18 column
198 (Waters Corp., Milford, MA) maintained at $35\text{ }^\circ\text{C}$. The mobile
199 phase consisted of A (water (Thermo Fisher Scientific,
200 Waltham, MA) + 0.1% formic acid (Sigma-Aldrich, St. Louis,
201 MO)) and B (acetonitrile (Thermo Fisher Scientific, Waltham,
202 MA) + 0.1% formic acid). A binary gradient was used from 0
203 to 10 min at the following conditions: 0–1 min 10% B, linear
204 gradient to 90% B at 8 min, 8.5 min return to initial conditions.
205 The mass spectrometer was operated in positive ion mode with
206 electrospray ionization. The mass range was 100–1400 m/z ,
207 and the source conditions were set to capillary voltage 3.0 V,
208 cone voltage 30 V, source offset 80, source temperature 125
209 $^\circ\text{C}$, desolvation temperature 400 $^\circ\text{C}$, cone gas 50 L/h,
210 desolvation gas 500 L/h, and nebulizer 6 bar. Data were
211 collected in MSe mode with a 0.2 s cycle time and a collision
212 energy ramp at 20–45 V in the high energy function. Leucine
213 enkephalin was infused at 5 $\mu\text{L}/\text{min}$ for mass correction at 20 s
214 intervals with a 0.2 s cycle time. The data was analyzed with
215 Mass Lynx (V 4.1, Waters Corp., Milford MA).

216 **NADP⁺ Inhibition.** The effects of NADP⁺ on FbsI activity
217 were measured using the oxygen consumption assay. All
218 reactions consisted of 1 μM FbsI, 25 μM putrescine, 0–1000
219 μM NADPH, and 25 mM HEPES, pH 7.5. NADP⁺
220 concentrations were varied at 0, 250, 500, and 1000 μM .
221 Inhibition constants were calculated by plotting the data as
222 double-reciprocal plots.

Size-Exclusion Chromatography. A 750 μL sample of 5
223 mg/mL FbsI was injected onto a HiPrep 16/60 Sephacryl S-
224 200 HR column equipped to an AKTA Prime Plus (GE
225 Healthcare, Chicago, IL). The column was equilibrated in Gel
226 Filtration Buffer (50 mM potassium phosphate, 150 mM NaCl,
227 pH 7.5) at a flow rate of 1.0 mL/min. To quantify the
228 oligomeric state of FbsI, a standard curve was produced using a
229 high-molecular-weight gel filtration calibration kit (GE Health-
230 care, Chicago, IL) along with His⁶-TEV protease and RNase
231 (Sigma-Aldrich, St. Louis, MO). The standard curve contained
232 ferritin (440 kDa), aldolase (158 kDa), conalbumin (75 kDa),
233 His⁶-TEV protease (27 kDa), and RNase (13 kDa). Blue
234 dextran (~2000 kDa) was used to calculate the void volume of
235 the column. Fractions containing FbsI were confirmed by using
236 SDS-PAGE analysis. 237

Stopped-Flow Spectrophotometry. All stopped-flow
238 assays were performed with a SX20 stopped-flow spectropho-
239 tometer equipped with a photodiode array detector (Applied
240 Photophysics, Surrey, UK) housed inside an anaerobic
241 glovebox (COY Laboratories, Grass Lake, MI). Prior to
242 performing assays, the sample-handling unit of the instrument
243 was made anaerobic by scrubbing oxygen with a mixture of
244 dextrose (Thermo Fisher Scientific, Waltham, MA) and
245 glucose oxidase (Sigma-Aldrich, St. Louis, MO) from
246 *Aspergillus niger*. Buffer solutions were made anaerobic using
247 a Schlenk line apparatus as described previously.²³ In short,
248 solutions sealed in Büchner flasks were deoxygenated with four
249 cycles of high vacuum pressure (4 min) and ultrapure argon (1
250 min). FbsI samples were deoxygenated with 15 cycles of high
251 vacuum pressure (2 s) and ultrapure argon (4 s). NAD(P)H
252 and putrescine were prepared by dissolving in anaerobic 25
253 mM HEPES, pH 7.5 buffer. All stopped-flow experiments were
254 performed at room temperature ($22 \pm 2\text{ }^\circ\text{C}$). 255

For the reductive half-reaction, 17 μM FbsI was mixed with
256 62.5–2000 μM NADPH or NADH using the single mixing
257 mode. For assays in the presence of substrate, 25 μM
258 putrescine was incubated with FbsI prior to mixing with
259 NADPH. Spectra from 190–800 nm were collected on a
260 logarithmic scale for 100 s (NADPH) or 250 s (NADH).
261 Traces at 450 nm were fit with a double-exponential decay
262 equation (eq 3). For eq 3, a_1 is the amplitude for the first
263 defined phase, $k_{\text{obs}1}$ is the observed reaction rate of the first
264 phase, a_2 is the amplitude for the second phase, $k_{\text{obs}2}$ is the
265 observed reaction rate of the second phase, t is the assay time,
266 and C is the final absorbance. 267

$$\text{Abs} = a_1 e^{-k_{\text{obs}1} t} + a_2 e^{-k_{\text{obs}2} t} + C \quad (3) \quad 268$$

For the oxidative half-reaction, 17 μM FbsI was first mixed
269 with 34 μM anaerobic NADPH to fully reduce the enzyme.
270 Oxygen saturated buffer was prepared by flushing with pure
271 oxygen gas for 1 h at $0\text{ }^\circ\text{C}$ with constant stirring, creating a 1.2
272 mM dissolved O_2 concentration in the buffer. Using the single
273 mixing mode, reduced enzyme was mixed with 25–600 μM
274 oxygen for 500 s (no putrescine) or 250 s (with putrescine).
275 Traces at 370 and 450 nm were fit with either a single-
276 exponential rise equation (eq 4) or a double-exponential rise
277 equation (eq 5). For eq 4, a is the amplitude, k_{obs} is the
278 observed reaction rate, t is the assay time, and D is the initial
279 absorbance. For eq 5, a_1 is the amplitude for the first phase,
280 $k_{\text{obs}1}$ is the observed reaction rate of the first phase, a_2 is the
281 amplitude for the second phase, $k_{\text{obs}2}$ is the observed reaction
282 rate of the second phase, t is the assay time, and D is the final
283 absorbance. 284

$$285 \quad \text{Abs} = a(1 - e^{-k_{\text{obs}}t}) + D \quad (4)$$

$$286 \quad \text{Abs} = a_1(1 - e^{-k_{\text{obs}_1}t}) + a_2(1 - e^{-k_{\text{obs}_2}t}) + D \quad (5)$$

287 **Crystallization.** Initial screening of FbsI using Crystal
288 Screen 1 and 2 kits and the Index kit (Hampton Research) was
289 done with 6.5 and 12 mg/mL FbsI in the presence of 5 mM
290 NADP⁺. A drop ratio of 1:1 protein:screening solution was
291 used. Small, yellow crystals formed in a condition containing
292 0.05 M ammonium sulfate, 0.05 M Bis-Tris pH 6.5, and 30%
293 pentaerythritol ethoxylate (15/4 EO/OH). The crystals were
294 cryoprotected by creating a mixture of 80% reservoir solution
295 and 20% PEG 200 by taking 8 μ L of the screening condition
296 from the reservoir and adding 2 μ L of 100% PEG 200. This
297 solution was added to the crystals, and after a minute, the
298 crystals were flash-cooled in liquid nitrogen.

299 **X-ray Crystal Structure Determination.** X-ray diffrac-
300 tion data from a crystal of the NADP⁺ complex were collected
301 at Advanced Photon Source beamline 24-ID-E using an Eiger-
302 16 M detector. The data were processed with XDS²⁴ and
303 AIMLESS.²⁵ The space group is P₂₁ 2₁ 2₁ with the unit cell
304 dimensions listed in Table 1. Analysis of solvent content
305 suggested the asymmetric unit contains four FbsI chains with a
306 Matthews coefficient of 2.7 $\text{\AA}^3/\text{Da}$ and 54% solvent content.²⁶
307 Data processing statistics are summarized in Table 1.

308 Initial phases for the FbsI-NADP⁺ complex were calculated
309 using molecular replacement. A monomer search model was
310 generated from the structure of *Streptomyces sviveus* DesB in
311 complex with NADP⁺ (PDB ID 6XBB)²⁷ with Chainsaw²⁸
312 using the C γ -truncation option. FbsI and SsDesB are 47%
313 identical in amino acid sequence. Molecular replacement
314 calculations were performed with Phaser as implemented in
315 Phenix.^{29,30} Phaser identified a solution having four molecules
316 arranged as a tetramer with D₂ symmetry. The structure from
317 Phaser was completed through several cycles of iterative
318 modeling in Coot³¹ and refinement in Phenix. The ligands
319 FAD and NADP⁺ were refined with occupancy fixed at 1.0.
320 PEG fragments were modeled near the ϵ -amino group of
321 Lys188. The structure was validated using polder omit maps,³²
322 MolProbity,³³ and the PDB validation server.³⁴ Refinement
323 statistics are listed in Table 1. Coordinates and structure factor
324 amplitudes have been deposited in the PDB under accession
325 code 7US3.

326 **Small-Angle X-ray Scattering (SAXS).** A sample of FbsI
327 at 12 mg/mL was dialyzed against a buffer consisting of 25
328 mM HEPES, pH 7.5, 150 mM NaCl, and 1 mM TCEP. The
329 dialyzed sample was pipetted into a 96-well tray at nominal
330 concentrations in the range of 1–9 mg/mL. The dialysate was
331 reserved for measurement of the background SAXS curve.
332 Shutterless SAXS data collection was performed at 20 $^{\circ}$ C using
333 a Pilatus detector at beamline 12.3.1 of the Advanced Light
334 Source through the SIBYLS Mail-in High Throughput SAXS
335 program.³⁵ The total exposure time was 10 s per sample,
336 framed every 0.33 s (30 frames total). The wavelength was
337 1.234 \AA . Buffer-subtracted SAXS curves were averaged using
338 SAXS FrameSlice. PRIMUS³⁶ was used to perform Guinier
339 analysis, calculate the distance distribution function, and
340 estimate the molecular mass. The molecular mass was also
341 estimated using the SAXSMoW server.³⁷ Theoretical SAXS
342 curves were calculated using FoXS.³⁸ Models of the tetramer
343 including residues not observed in the crystal structure were
344 generated with AllosMod-FoXS using the default (most
345 conservative) settings. The SAXS data, $P(r)$ curves, and best

Table 1. X-ray Diffraction Data Collection and Refinement Statistics

Space group	P 2 ₁ 2 ₁ 2 ₁
Unit cell parameters (\AA)	$a = 124.83$ $b = 126.31$ $c = 140.25$
Wavelength (\AA)	0.97918
Resolution (\AA)	140.25–2.20 (2.24–2.20)
Observations ^a	902459 (32196)
Unique reflections ^a	111523 (4908)
$R_{\text{merge}}(I)$ ^a	0.235 (1.383)
$R_{\text{meas}}(I)$ ^a	0.268 (1.502)
$R_{\text{pim}}(I)$ ^a	0.095 (0.570)
Mean I/σ ^a	8.8 (1.3)
CC _{1/2} ^a	0.987 (0.466)
Completeness (%) ^a	99.3 (89.0)
Multiplicity ^a	8.1 (6.6)
No. of protein residues	1712
No. of atoms	
Protein	13 754
FAD	212
NADP ⁺	192
Water	603
R_{cryst} ^a	0.1817 (0.3064)
R_{free} ^{a,b}	0.2225 (0.3268)
RMSD bonds (\AA)	0.007
RMSD angle (deg)	0.890
Ramachandran plot ^c	
Favored (%)	96.65
Outliers (%)	0.12
Clashscore (PR) ^c	3.17 (99)
MolProbity Score (PR) ^c	1.73 (95)
Average B-factor (\AA^2)	
Protein	38.6
FAD	36.9
NADP ⁺	41.7
Water	36.9
PDB ID	7US3

^aValues for the outer resolution shell of data are given in parentheses.

^b5% test set. ^cFrom MolProbity. The percentile ranks (PR) for Clashscore and MolProbity score are given in parentheses.

fit models have been deposited in the SASBDB under the
accession codes listed in Table 4.³⁹

RESULTS

Expression, Purification, and Solution Molecular Weight. Recombinant FbsI was subcloned into the pET28a vector and expressed with an N-terminus His₆ affinity tag in *E. coli* BL21 (DE3) cells. The resuspended cell pellet was purified using Ni-NTA immobilized metal affinity chromatography (IMAC). Yellow fractions, indicative of flavin-bound protein, were collected and analyzed using SDS-PAGE, showing FbsI was purified at >95% homogeneity (Figure S1A). The protein yield for FbsI was 18 mg protein/liter of bacterial culture. The UV-visible absorbance spectrum of FbsI showed two characteristic peaks at 370 and 450 nm, further indicative of FAD bound protein (Figure S1B). The extinction coefficient for FbsI based on FAD concentration at pH 7.5 was determined to be 12.99 $\text{mM}^{-1} \text{cm}^{-1}$. The native molecular weight of FbsI in solution was estimated using size-exclusion chromatography. A standard curve was used to estimate a 364

Table 2. Steady-State Kinetic Parameters of FbsI Determined by the Oxygen Consumption and Product Formation Assays

Variable Substrate ^a	Fixed Substrate	K_m (μM)	k_{cat} (s^{-1})	k_{cat}/K_m ($\text{M}^{-1} \text{s}^{-1}$)	K_i (μM)
Oxygen consumption					
Putrescine	NADPH	3.0 ± 2.0	0.60 ± 0.10	$208\,000 \pm 33\,000$	120 ± 50
Cadaverine	NADPH	9.0 ± 2.0	0.54 ± 0.20	$58\,000 \pm 11\,000$	220 ± 70
NADPH	Putrescine	60 ± 10	0.70 ± 0.04	$11\,400 \pm 2\,500$	-
NADH	Putrescine	55 ± 20	0.30 ± 0.10	$5\,000 \pm 400$	-
Product formation assay					
Putrescine	NADPH	6.0 ± 2.0	0.65 ± 0.04	$102\,000 \pm 27\,000$	$1\,900 \pm 500$
Cadaverine	NADPH	8.0 ± 0.70	0.12 ± 0.06	$14\,300 \pm 820$	-
NADPH	Putrescine	58 ± 14	0.70 ± 0.10	$12\,000 \pm 1\,000$	-
NADH	Putrescine	200 ± 90	0.37 ± 0.062	$1\,850 \pm 650$	-

^aFixed concentrations were at 0.5 mM NADPH or 0.025 mM putrescine.




Figure 2. Steady-state kinetic analysis of FbsI. (A) Measurement of initial rate conditions when varying putrescine (black circle) and cadaverine (blue square) concentrations and (B) NADPH (black solid circle) and NADH (blue open circle) concentrations using the oxygen consumption assay. (C) Measurement of initial rate conditions when varying putrescine (black circle) and cadaverine (blue square) concentrations and (D) NADPH (black solid circle) and NADH (blue open circle) concentrations using the hydroxylated amine product formation assay.

365 molecular weight of FbsI in solution of $\sim 248\,000$ Da,
 366 consistent with FbsI forming a tetramer in solution (monomer
 367 MW = $53\,500$ Da) (Figure S2).

368 **Steady-State Kinetic Analysis.** The steady-state kinetic
 369 parameters for FbsI were determined using an oxygen
 370 consumption assay. All assays were performed using 25 mM
 371 HEPES, pH 7.5, and an enzyme concentration of 1 μM . For
 372 the oxygen consumption assay, substrate selectivity of FbsI was
 373 determined by varying concentrations of putrescine, cadaver-

ine, L-ornithine, and L-lysine. The enzyme showed the greatest
 374 activity with putrescine, with an apparent K_m of 3.0 ± 2.0 μM
 375 and a k_{cat}/K_m of $208\,000 \pm 30\,000$ $\text{M}^{-1} \text{s}^{-1}$ (Table 2). FbsI
 376 showed a nearly 4-fold reduction in the catalytic efficiency with
 377 cadaverine when compared to putrescine (Figure 2A). No
 378 significant changes in activity were detected when varying L-
 379 lysine and L-ornithine concentrations, as the estimated k_{obs} of
 380 ~ 0.1 s^{-1} for these compounds is equivalent to background
 381 NADPH oxidation (not shown). Preference for the reducing
 382




Figure 3. Measuring flavin reduction using stopped-flow spectroscopy. (A) Bleaching of the peak at 450 nm over 100 s following reduction of FbsI with 2 mM NADPH. The yellow line represents fully oxidized flavin, while the black line represents reduced flavin. (B) Traces at 450 nm when titrating with increasing concentrations of NADPH over 100 s. Traces were fit with eq 3, as shown by the solid black line. (C) Measurement of rapid-reaction rate constants when titrating increasing concentrations of NADPH (black circle) and NADH (blue square) against oxidized FbsI.

383 cofactors NADH and NADPH was also measured (Figure 2B).
 384 The K_m values for NADH and NADPH are nearly identical;
 385 however, the k_{cat} is ~ 2.3 -fold faster with NADPH compared to
 386 NADH (Table 2). The effect of various concentrations of
 387 $NADP^+$ on the kinetic parameters was measured to determine
 388 the mode of inhibition by $NADP^+$. The double-reciprocal plot
 389 analysis shows that the lines have different slopes and the same
 390 y -intercept, consistent with $NADP^+$ being a competitive
 391 inhibitor against NADPH (Figure S3).

392 The steady-state kinetic parameters were also measured by
 393 monitoring formation of the product *N*-hydroxyputrescine
 394 using a modified Csaky iodine oxidation assay. Putrescine and
 395 cadaverine concentrations were varied the same as with the
 396 oxygen consumption assay (Figure 2C). The k_{cat}/K_m when
 397 varying putrescine was over 7-fold faster than when varying
 398 cadaverine (Table 2). No product formation was observed
 399 when varying *L*-lysine or *L*-ornithine concentrations (not
 400 shown). When varying reducing cofactor concentration, the
 401 k_{cat} for NADPH was ~ 2 -fold higher than that of NADH, and
 402 the K_m of NADPH was ~ 4 -fold lower than that of NADH
 403 (Figure 2D, Table 2). The latter trend was not observed with
 404 the oxygen consumption assay, where the K_m values for the
 405 two reducing cofactors were nearly identical (Table 2). This
 406 difference is likely due to the production of H_2O_2 by FbsI, a
 407 process known as uncoupling. The coupling efficiency, taken as
 408 a ratio of k_{cat} between the iodine oxidation and oxygen
 409 consumption assays, for putrescine is $108 \pm 4\%$ compared to
 410 $22 \pm 3\%$ for cadaverine, suggesting that uncoupling occurs
 411 when cadaverine is present. These results suggest that
 412 putrescine is the preferred substrate.

413 **Detection of *N*-Hydroxyputrescine.** To further confirm
 414 that putrescine is being hydroxylated by FbsI to form *N*-
 415 hydroxyputrescine, LC-MS was utilized. Reactions containing
 416 putrescine along with controls without NADPH or FbsI
 417 present were derivatized using Fmoc-Cl and submitted for LC-
 418 MS analysis. All three reaction conditions had a peak with an
 419 m/z of 533.24 amu, corresponding to the structure of Fmoc-
 420 putrescine ($C_{34}H_{32}N_2O_4$). Only the reaction containing
 421 putrescine, NADPH, and FbsI contained a peak with an m/z
 422 of 549.24 amu, which is indicative of Fmoc-*N*-hydroxyput-
 423 rescine ($C_{34}H_{32}N_2O_5$) (Figure S4).

Reductive Half-Reaction. Changes in flavin reduction for 424
 FbsI were measured using a stopped-flow spectrophotometer 425
 under anaerobic conditions. Bleaching of the prominent peak 426
 at 450 nm was observed when titrating oxidized FbsI with 427
 anaerobic NADPH and NADH (Figure 3A). The reduction 428 f3
 process occurred with a fast and slow phase, with the fast phase 429
 representing $\sim 80\%$ of the absorbance changes. The slow and 430
 minor phase did not change as a function of NADPH 431
 concentrations and had a value of $\sim 0.2 s^{-1}$. The rate constant 432
 for flavin reduction and binding affinities of the reducing 433
 cofactors are listed in Table 3. Increases in the k_{obs} (for the fast 434 f3

Table 3. Rapid-Rate Kinetic Parameters for the Reductive Half-Reaction of FbsI

Variable Substrate	Fixed Substrate	K_D (μM)	k_{red} (s^{-1})
NADPH	-	500 ± 70	4.0 ± 0.20
NADPH	Putrescine	400 ± 100	3.0 ± 0.20
NADH	-	800 ± 100	0.50 ± 0.01

phase) were seen as increasing NADPH concentrations were 435
 tested (Figure 3B). A similar trend in reduction was also 436
 observed with NADH (data not shown). The rate of reduction 437
 (k_{red}) of FbsI was nearly 8-fold faster with NADPH as the 438
 reducing cofactor compared to NADH (Figure 3C). Addition- 439
 ally, the K_D for NADH is approximately 1.6-fold higher 440
 than that of NADPH. The presence of putrescine does not 441
 significantly change the K_D value for NADPH, while the k_{red} 442
 only decreases by $\sim 25\%$. 443

Oxidative Half-Reaction. Formation of the reactive C4a- 444
 hydroperoxyflavin intermediate along with flavin reoxidation 445
 was monitored using stopped-flow spectroscopy. Increases in 446
 the peaks at 370 and 450 nm were seen after titrating reduced 447
 FbsI with increasing concentrations of oxygen. In the absence 448
 of putrescine, an increase in the absorbance at 370 nm was 449
 observed (Figure 4A). This peak is consistent with the 450 f4
 formation of the C4a-hydroperoxyflavin intermediate, where 451
 the rate constant for this process (k_{OOH}) was $0.28 \pm 0.02 s^{-1}$ at 452
 $250 \mu M O_2$.^{40–42} This was followed by an increase in 453
 absorbance at 450 nm, which corresponds to flavin oxidation 454
 via the release of hydrogen peroxide ($k_{H_2O_2}$), with a maximum 455
 value of $0.02 \pm 0.004 s^{-1}$ (Figure 4B). In the presence of 456




Figure 4. Measuring FbsI oxidation using stopped-flow spectroscopy. (A) Oxidation spectra of FbsI in the absence of putrescine at $250 \mu\text{M O}_2$ over 500 s. Arrows show the increase in absorbance at 370 and 450 nm over time. (B) Isolated traces at 370 nm (C4a-hydroperoxyflavin) and 450 nm (flavin reoxidation) in the absence of putrescine. Traces were fit with eq 4. (C) Oxidation spectra of FbsI in the presence of putrescine at $250 \mu\text{M O}_2$ over 250 s. (D) Isolated traces at 370 and 450 nm in the presence of putrescine. Traces were fit with eq 5.

457 putrescine, the C4a-hydroperoxyflavin peak formed much
458 faster, as the k_{OOH} increased ~ 6 -fold to $1.56 \pm 0.26 \text{ s}^{-1}$ at 250
459 $\mu\text{M O}_2$ (Figure 4C). Because putrescine is hydroxylated by the
460 C4a-hydroperoxyflavin intermediate, the increase in absorb-
461 ance at 450 nm in the presence of putrescine represents flavin
462 dehydration (k_{OH}). This process of flavin oxidation occurred in
463 two distinct phases, one fast ($0.400 \pm 0.002 \text{ s}^{-1}$) and the other
464 slow ($0.030 \pm 0.003 \text{ s}^{-1}$) (Figure 4D).

465 **Crystal Structure of FbsI.** The structure of FbsI
466 complexed with NADP^+ was determined at 2.20 \AA resolution.
467 Electron density supported the modeling of residues Gln4
468 through Val430 in all four polypeptide chains in the
469 asymmetric unit without breaks (out of 466 total residues).
470 FbsI exhibits the expected three-domain fold observed in other
471 NMOs (Figure 5A). The two major domains each exhibit a
472 Rossmann-like $\alpha/\beta/\beta$ three-layer sandwich. The N-terminal
473 Rossmann-like domain binds FAD, while the C-terminal one
474 binds NADP^+ . The FAD domain also supplies the amino acid
475 substrate binding site. The smaller third domain consists of
476 three α -helices (residues 70–114) and is involved in
477 oligomerization (Figure 5A, right). The oligomerization
478 domain contacts the amino acid substrate binding site,
479 suggesting that oligomerization may be important for catalytic
480 function.

The PDB was searched for structural neighbors of FbsI using
PDBFold.⁴³ FbsI is most similar in both sequence and
structure to the SsDesB and DfoA cadaverine *N*-hydroxylases
(Table S1). FbsI is nearly 50% identical in sequence to these
enzymes, and the structures align with a C- α RMSD of less
than 1.0 \AA (Figure S5A,B). FbsI shows lower similarity to
ornithine and lysine *N*-hydroxylases. In this case, the sequence
identity is less than 30%, and the RMSD is $\sim 2.0 \text{ \AA}$ (Figure
S5C,D). These results are consistent with the substrate of FbsI
being more similar to cadaverine than either ornithine or
lysine.

Oligomeric Structure of FbsI. FbsI and its structural
neighbors in the PDB (Table S1) all form a D_2 symmetry
tetramer in the crystal (Figure 5B). In each case, the
homotetramer is predicted to be stable in solution based on
analysis of protein-protein interfaces using PDBEPIA.⁴⁴ We
note that light scattering measurements suggested that PvdA is
monomeric at 4.7 mg/mL .⁴⁵ We are not aware of other
biophysical characterizations of the oligomeric structures of
NMOs. Thus, it is possible that PvdA, and potentially other
related NMOs, exhibit a concentration-dependent self-
association equilibrium in solution that favors the tetramer at
the high protein concentrations used in crystallization. We




Figure 5. Fold and oligomeric structure of FbsI. (A) Protomer of FbsI complexed with FAD and NADP⁺. The protein is colored using a rainbow scheme with blue at the N-terminus and red at the C-terminus. FAD and NADP⁺ are shown in yellow and gray sticks, respectively. (B) The tetramer of FbsI viewed along its three mutually orthogonal twofold axes.

2–13% of the theoretical molecular weight of the FbsI tetramer (214 kDa), consistent with size-exclusion chromatography. Thus, the SAXS data are consistent with FbsI existing in solution as an ellipsoidal-shaped tetramer over the concentration range of 1–9 mg/mL. However, the discrepancy between the R_g from SAXS of 41–42 Å and that of the D₂ tetramer of only 36 Å suggests that the crystallographic D₂ tetramer does not fully account for the oligomeric structure of FbsI in solution.

We considered the possibility that the incompleteness of the crystal structure contributes to the suboptimal fit to the experimental SAXS profile. The crystal structure lacks 23 residues at the N-terminus and 15 residues at the C-terminus due to weak electron density. These disordered residues account for about 8% of the polypeptide chain. Schneidman-Duhovny et al. have stressed that modeling of a complete structure is critical for comparison of computed and experimental profiles.⁴⁷ The missing termini were modeled using AllosMod-FoXS⁴⁸ as extended polypeptide chains (Figure 7B), and their inclusion increased the R_g to 40 Å, which is within 1–2 Å of the SAXS value. The calculated SAXS profiles exhibit improved qualitative agreement with the experimental curves (Figure 7B) and substantially lower goodness-of-fit parameters (χ^2) for all six samples (Table 5). These are consistent with the D₂ tetramer being the predominant oligomeric structure of FbsI in solution.

We also considered the possibility that another tetrameric species—one with a larger R_g —is present in solution either alone or in equilibrium with the D₂ tetramer. Analysis of the protein-protein interfaces in the crystal with PDBEPIA revealed an extended, asymmetric tetramer with an R_g of 46 Å (Figure 7C). The extended tetramer has very poor agreement with the experimental SAXS data (Figure 7C), as evidenced by χ^2 values of 2–35, compared to 0.1–1.1 for the complete D₂ tetramer (Table 5), indicating that this species does not predominate in solution. Modeling an ensemble of D₂ and extended tetramers using MultiFoXS did not improve the fits (i.e., MultiFoXS did not return a two-body result). These results suggest that the extended four-body assembly results from crystal packing and confirm that the D₂ tetramer is the predominant form of FbsI in solution.

Conformations and Interactions of FAD and NADP⁺.

FbsI was cocrystallized with NADP⁺, and the electron density maps clearly indicated that both FAD and NADP⁺ were bound

504 investigated this possibility for FbsI using small-angle X-ray scattering (SAXS).

506 The solution structural parameters of FbsI were determined from SAXS. SAXS data were collected at protein concentrations of 1–9 mg/mL (Table 4). The shape of the SAXS curve does not vary substantially with protein concentration (Figure 6A). In particular, the low- q region does not show evidence of concentration-dependent behavior, such as self-association (Figure 6B). The radius of gyration (R_g) from both Guinier analysis (Figure 6C) and the pair distribution function ($P(r)$) is 41–42 Å (Table 4). For reference, the D₂ symmetry tetramer in the crystallographic asymmetric unit has an R_g of 36 Å. The $P(r)$ curves are monomodal at all protein concentrations with a peak at $r = 50$ –51 Å, consistent with the particle in solution having a compact, ellipsoidal shape (Figure 6D). The molecular weight from SAXS is 186–208 kDa based on Bayesian inference⁴⁶ and 218–231 kDa based on the SAXS MoW method³⁷ (Table 4). This range is within

Table 4. Solution Structural Properties of FbsI from SAXS

Conc. (mg/mL)	1	3	5	6	8	9
Guinier analysis ^a						
qR_g range	0.55–1.27	0.58–1.27	0.46–1.29	0.58–1.28	0.53–1.29	0.53–1.27
R_g (Å)	41.3 ± 1.2	41.3 ± 0.5	41.8 ± 0.5	41.6 ± 0.4	42.1 ± 0.4	42.3 ± 0.3
$P(r)$ analysis ^a						
Points used	1–238	1–237	1–238	1–233	1–234	1–233
D_{\max} (Å)	150	150	150	154	155	150
R_g (Å)	41.5	41.5	41.5	41.7	41.8	42.2
Porod Vol. (Å ³) ^a	394 × 10 ³	395 × 10 ³	391 × 10 ³	392 × 10 ³	394 × 10 ³	397 × 10 ³
MW (kDa)						
Bayesian Inf. ^{a,b}	185.8 (–13%)	185.8 (–13%)	185.8 (–13%)	208.0 (–3%)	208.0 (–3%)	185.8 (–13%)
SAXSMoW ^{c,b}	218.4 (+2%)	224.0 (+5%)	225.0 (+5%)	228.7 (+7%)	230.6 (+8%)	226.5 (+6%)
SASBDB	SASDNA9	SASDNB9	SASDNC9	SASDND9	SASDNE9	SASDNF9

^aCalculated with Primus. ^bThe percent difference from the theoretical MW of the tetramer (214 kDa) is listed in parentheses. ^cCalculated with the SAXSMoW server




Figure 6. SAXS data on FbsI. (A) SAXS curves measured at protein concentrations in the range of 1–9 mg/mL. These data with uncertainties included are shown in Figure S7. (B) SAXS curves scaled for protein concentration highlighting the agreement at low q . (C) Guinier plots. (D) Distance distribution functions. The oligomeric structure of FbsI in solution was investigated further by calculating theoretical SAXS curves from models derived from the crystal structure. The curve calculated from the D_2 crystal tetramer shows reasonable overall agreement with the experimental data in that it accounts for the minimum near $q = 0.104 \text{ \AA}^{-1}$ and the peak near $q = 0.125 \text{ \AA}^{-1}$ (Figure 7A). The fit is poorer in the Guinier region, as expected given the 6 \AA R_g mismatch.

566 to the enzyme (Figure 8A). The conformations of these ligands
 567 were unambiguously defined by the electron density, except for
 568 the carboxamide of NADP^+ . The electron density for the
 569 carboxamide was somewhat variable, being the strongest in
 570 chains C and D (Figure S6) and weaker in chains A and B
 571 (Figure S6). The density in chains C and D was therefore used
 572 to determine the conformation of the carboxamide, within a
 573 dihedral rotation of 180° . The dihedral angle ambiguity was
 574 then resolved using hydrogen bonding. In particular, an atom
 575 of the carboxamide is within hydrogen bonding distance of the
 576 FAD O4 and N5 atoms. Since both FAD atoms are obligate
 577 hydrogen bond acceptors, the interacting atom of the
 578 carboxamide was assigned to be a hydrogen bond donor, i.e.,
 579 the $-\text{NH}_2$ group (Figure S6).

580 The conformations of the FAD and NADP^+ in FbsI are
 581 almost identical to those in the 2.37 \AA resolution structure of
 582 cadaverine hydroxylase from *Streptomyces sviveus* (SsDesB). In
 583 both structures, the FAD adopts the “in” conformation, in
 584 which the *si*-face of the isoalloxazine is buried and the *re*-face is
 585 available to participate in catalysis (Figure 8B); this is the most
 586 common conformation observed in NMO structures.⁴⁹ The *si*-
 587 face of the isoalloxazine in FbsI and SsDesB is braced by Leu,
 588 Trp, and His side chains, the latter two also hydrogen bonding
 589 to the FAD ribityl O4' (Figure 8B). The B side of the NADP^+
 590 nicotinamide packs against the *re*-face of the isoalloxazine; this
 591 is the same arrangement seen in the other NMO structures.

The nicotinamide sits below an Arg-Glu ion pair and its
 592 carboxamide hydrogen bonds with the N5 edge of the FAD.
 593 Two glutamine side chains also help confine the nicotinamide,
 594 although we note that the conformation of Gln56 is somewhat
 595 uncertain in FbsI due to weak electron density; it is possible
 596 that this side chain samples different rotamers in the NADP^+
 597 complex. The adenosine 2'-phosphoryl of NADP^+ interacts
 598 with two lysine side chains (Figure 8C). Asn264 may provide
 599 additional stabilization, although the interaction distance is
 600 long for a hydrogen bond (3.9 \AA). Interestingly, Asn264 is
 601 replaced in the SsDesB and DfoA cadaverine hydroxylases by
 602 lysine, enabling them to form an additional ion pair with the
 603 adenosine 2'-phosphoryl. Finally, we note that the conserved
 604 water of the Rossmann fold⁵⁰ is present in the NADPH site of
 605 FbsI (as well as in cadaverine hydroxylase and ornithine
 606 hydroxylase). This water molecule bridges the pyrophosphate
 607 of the dinucleotide with the glycine-rich loop of the Rossmann
 608 fold (Figure 8C).
 609

DISCUSSION

In this work, we presented the biochemical and structural
 611 characterization of the aliphatic diamine *N*-hydroxylase FbsI.
 612 The catalytic function of FbsI is essential for the biosynthesis
 613 of functional fimsbactins in *A. baumannii*.⁹ The enzyme activity
 614 studies revealed that this enzyme does not use lysine or
 615 ornithine as substrates, preferring aliphatic diamines instead.
 616




Figure 7. Comparison of the experimental SAXS curves (circles) with theoretical SAXS curves calculated from atomic models (red curves). For clarity, only the data for the lowest (1 mg/mL) and highest (9 mg/mL) protein concentrations are shown. (A) SAXS curves calculated from the crystal D₂ tetramer with missing residues added by AllosMod. (B) SAXS curves calculated from the extended four-body assembly present in the crystal lattice.

Table 5. Goodness-of-Fit Parameters from FoXS (χ^2) from Fitting the SAXS Data with Atomic Models

Conc. (mg/mL)	1	3	5	6	8	9
Crystal D ₂ tetramer	0.29	1.4	1.3	1.8	2.6	3.9
AllosMod D ₂ tetramer	0.090	0.32	0.33	0.57	0.84	1.1
Extended tetramer	1.8	11.2	11.6	21.0	29.3	35.0




Figure 8. Electron density and interactions for FAD and NADP⁺ bound to FbsI. (A) Polder omit map for FAD (yellow) and NADP⁺ (gray) in chain D contoured at 4 σ . (B) Environment around the isoalloxazine-nicotinamide interface. The dashed lines indicate interactions within a 3.2 Å cutoff. (C) Environment around the ADP part of NADP⁺. The dashed lines indicate interactions within a 3.2 Å cutoff, except where noted.

Based on the catalytic efficiency values calculated with the 617 oxygen consumption assays, putrescine is the preferred 618 substrate with a k_{cat}/K_m value \sim 3.5-fold higher than 619 cadaverine. Using the iodine oxidation assay that measures 620 the amount of hydroxylated product, it was noted that the $k_{cat}/$ 621




Figure 9. Proposed catalytic mechanism of FbsI. (A) The reaction starts by binding of NADPH to oxidized FbsI with relative low affinity. (B) Hydride transfer takes place, producing reduced FbsI in complex with NADP⁺. (C) Putrescine binds and the reduced flavin reacts with molecular oxygen via an electron transfer step to “activate” the oxygen and form the C4a-hydroperoxyflavin intermediate. (D) Hydroxylation occurs, resulting in the production of *N*-hydroxyputrescine and a C4a-hydroxyflavin. (E) The penultimate step is flavin dehydration to reform oxidized flavin and release of hydroxylated putrescine. (F) The last step in the cycle is release of NADP⁺. (G) If putrescine is not present in the active site or is in the incorrect orientation, then the C4a-hydroperoxyflavin intermediate will decay, releasing H₂O₂.

622 K_m for cadaverine decreased ~ 7 -fold as compared to
 623 putrescine (Table 2). This decrease was mainly due to a
 624 reduction in the k_{cat} value. The difference in the k_{cat} value from
 625 the oxygen consumption assay and the iodine oxidation assay
 626 originated from uncoupling, where hydrogen peroxide is
 627 produced and no hydroxylation takes place.^{51,52} This
 628 uncoupling likely takes place due to the structural similarities
 629 of cadaverine and putrescine, whereas cadaverine can fit within
 630 the active site but is likely not appropriately positioned in
 631 comparison to putrescine to the C4a of the isoalloxazine ring
 632 on the flavin, resulting in breakdown of the C4a-hydro-
 633 peroxyflavin intermediate. These results are consistent with
 634 putrescine being the preferred substrate for FbsI. The k_{cat}/K_m
 635 values for NADPH are ~ 2 -fold higher than for NADH,
 636 suggesting a slight preference for NADPH. We performed
 637 product inhibition experiments with various concentrations of
 638 NADP⁺ as a function of NADPH concentrations. The double-
 639 reciprocal plot only showed changes in the slope, consistent
 640 with NADP⁺ binding to the same enzyme form as NADPH
 641 and being the last product to be released during catalysis.

642 Because FbsI is a flavin-dependent enzyme, we used
 643 stopped-flow spectrophotometry to measure the rate constant
 644 for formation and decay of the various redox intermediates in
 645 the FbsI reaction. The initial steps are the binding of
 646 NAD(P)H, reduction of the flavin, and formation of the
 647 reduced FbsI:NADP⁺ complex, which completes the reductive
 648 half-reaction. Flavin reduction (k_{red}) occurred in two distinct
 649 phases. The k_{red} value was approximately 8-fold higher when
 650 FbsI was reduced with NADPH vs NADH. In addition, the K_D
 651 for NADPH was 1.6-fold lower than that of NADH. These
 652 results indicate that FbsI displays a minor preference for
 653 NADPH. We also show that substrate binding has only minor
 654 effects on the rate of flavin reduction and the K_D of NADPH.
 655 The presence of two phases for flavin reduction has been
 656 previously observed in some Class B FMOs.^{22,53} The fast
 657 phase, occurring within the first second, is faster than the k_{cat}
 658 measured in the steady-state kinetic assays. The slow phase,
 659 making up approximately 25% of the amplitude change for the
 660 reduction, occurs between the first and tenth seconds of
 661 reduction. We hypothesize that this slow phase is present due

to a population of FbsI that is in a different conformation
 partially inactive.

In the oxidative half-reaction, the reduced FbsI:NADP⁺
 complex reacts with oxygen presumably generating a C4a-
 hydroperoxy intermediate, which if stable, can be observed. In
 the absence of putrescine, an increase in absorbance at 370 nm
 occurred in a single phase, and this peak is characteristic of the
 C4a-hydroperoxy intermediate in other NMOs (Figure
 4).^{41,54,55} This intermediate is stable and decays slowly to
 regenerate the oxidized flavin (monitored at 450 nm) by
 releasing hydrogen peroxide. When putrescine was present,
 formation of the C4a-hydroperoxy intermediate formation
 (k_{OOH}) occurred ~ 8 -fold faster. The enhancement in the k_{OOH}
 value has also been observed in other NMOs. It was suggested
 for the related ornithine hydroxylase, Sida, that substrate
 binding enhances a conformational change that favors
 reactivity with oxygen.⁵⁶ The absorbance changes at 450 nm
 in the presence of putrescine occur in two phases, with the fast
 phase at $0.400 \pm 0.002 \text{ s}^{-1}$ and the slow phase at 0.030 ± 0.003
 s^{-1} . We attribute the slow phase to a population of protein with
 lower activity. The fast phase is similar in value to the k_{cat} for
 FbsI ($0.60 \pm 0.10 \text{ s}^{-1}$). These results suggest that dehydration
 of the C4a-hydroxyflavin intermediate may be partially rate-
 limiting. Another possible explanation is that hydroxylation of
 putrescine, rather than flavin dehydration, could be a rate-
 limiting step in the oxidative half-reaction. This has been
 observed with some two-component flavin monooxygenase
 systems; however, this has not been well explored in single-
 component FMOs.^{57,58}

The results from the stopped-flow kinetic analysis are
 consistent with FbsI belonging to the Class B NMOs, as is the
 crystal structure showing two Rossmann domains for binding
 FAD and NADPH. The catalytic cycle of this group of
 enzymes utilize the “bold mechanism,” where flavin reduction
 can occur in the absence of substrate and NADP⁺ remains
 bound during catalysis, playing a role in the stabilization of the
 C4a-hydroperoxyflavin intermediate.^{56,59} In contrast, Class A
 FMOs such as *p*-hydroxybenzoate hydroxylase (PHBH) utilize
 the “cautious mechanism” of flavin reduction, which requires
 substrate binding to allow the flavin to be reduced.⁶⁰ The

kinetic characterization of FbsI is consistent with the catalytic cycle shown in Figure 9.

The structure of FbsI resembles that of other members of the NMO family^{27,49,52,61,62} and provides clues about cofactor selectivity. The selectivity of FbsI for NADPH is rather small (3-fold), compared to other NMOs, which tend to show selectivity of 40-fold or higher.⁶³ For example, the SidA ornithine hydroxylase shows a 70-fold selectivity for NADPH over NADH based on the K_D . In both SidA and FbsI, three residues make four interactions with the 2'-phosphoryl group of NADPH; however, the strength of these interactions differs in the two enzymes (Figure S8). In SidA, the 2'-phosphoryl is stabilized by three electrostatic interactions within 3.0 Å, including a bidentate ion pair with Arg279 (Figure S8A).⁴⁹ In contrast, only one interaction is within 3.0 Å in FbsI (Figure S8B). The apparently greater stabilization of the 2'-phosphoryl in SidA may account for its greater preference for NADPH.

Attempts to obtain a structure of FbsI with putrescine were unsuccessful. Nevertheless, the structure may provide insight into substrate recognition. We docked a model of putrescine into the active site of FbsI based on the structure of SidA complexed with L-ornithine (PDB ID 6X0J).⁶⁴ The model predicts that Asp390 and Thr240 provide interactions that anchor the distal amino group of the substrate in the active site tunnel (Figure S9). The lack of obligate hydrogen bond donors or positively charged side chains in this region is consistent with the lack of activity with L-ornithine and L-lysine, which contain carboxylate groups. The side chains of Met230, Leu232, and Ile57 form nonpolar contacts with the aliphatic part of the substrate. The active site tunnel seems large enough to also accommodate cadaverine, which differs from putrescine by the addition of a methylene group. This is consistent with FbsI activity being observed with cadaverine.

In conclusion, we present the first kinetic and structural characterization of a flavin-dependent putrescine N-hydroxylase involved in siderophore biosynthesis. FbsI's high substrate selectivity for putrescine support its *in vivo* role in synthesizing fimsbactins for *A. baumannii*. Additionally, we show FbsI to belong to the Class B FMOs, based on the protein fold and the ability to reduce its flavin prosthetic group in the absence of substrate. The crystal structure further reveals similarities to other aliphatic diamine or amino-acid-catalyzing NMOs, showing conservation of this enzyme class among fungi and bacteria. SAXS and size-exclusion chromatography support crystallographic evidence that FbsI exists as a tetramer in solution at concentrations of 1 mg/mL or higher. Future studies probing substrate selectivity will further elucidate the mechanism of FbsI and facilitate inhibitor discovery.

ASSOCIATED CONTENT

Data Availability Statement

All processed data are included in this manuscript. Requests for raw data, further information, or reagents contained within the manuscript are available upon request from the corresponding authors.

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.biochem.2c00493>.

Comparison of sequence identity of similar NMOs to FbsI. Overview of protein purification and size-exclusion chromatography. Results of NADP⁺ inhibition study. LC-MS chromatograms for Fmoc-Cl derivatization.

Comparison of structural alignments of solved crystal structures to FbsI along with electron density maps for FAD and NADP⁺. SAXS curves for varying FbsI concentrations. Active site architectures identifying residues potentially involved in cofactor and putrescine binding (PDF)

Accession Codes

FbsI WP_001088061.1 (NCBI), SsDesB C9Z469 (NCBI), DfoA CBA23306 (NCBI), SidA AAT84594 (NCBI). All PDB and SASBDB accession codes are provided in the main text.

AUTHOR INFORMATION

Corresponding Authors

Pablo Sobrado – Department of Biochemistry and Center for Drug Discovery, Virginia Tech, Blacksburg, Virginia 24061, United States; orcid.org/0000-0003-1494-5382; Email: psobrado@vt.edu

John J. Tanner – Department of Biochemistry, University of Missouri, Columbia, Missouri 65211, United States; Department of Chemistry, University of Missouri, Columbia, Missouri 65211, United States; orcid.org/0000-0001-8314-113X; Email: tannerjj@missouri.edu

Authors

Noah S. Lyons – Department of Biochemistry and Center for Drug Discovery, Virginia Tech, Blacksburg, Virginia 24061, United States; orcid.org/0000-0003-2566-5087

Alexandra N. Bogner – Department of Biochemistry, University of Missouri, Columbia, Missouri 65211, United States; orcid.org/0000-0002-0358-422X

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acs.biochem.2c00493>

Author Contributions

A.N.B. and N.S.L.: Methodology, Investigation, Writing-Original Draft, Writing-Review & Editing, Visualization. P.S. and J.J.T.: Conceptualization, Formal analysis, Writing-Original Draft, Writing-Review & Editing, Visualization, Validation, Supervision, Project administration, Funding acquisition.

Funding

This research was supported by National Science Foundation grants CHE-2003658 (to P.S.) and CHE-2003986 (to J.J.T.).

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We would like to thank Dr. Timothy Wenczewicz and Jinping Yang from Washington University, St. Louis, MO for providing the plasmid for expression of FbsI and for helpful discussion. We also thank Drs. Rich Helm and Sherry Hildreth at the Virginia Tech Mass Spectrometry Incubator (MSI) for their assistance in performing and analyzing the LC-MS product detection experiments. N.S.L. was supported, in part, by the Cunningham Doctoral Fellowship from Graduate School at Virginia Tech. We thank Jonathan Schuermann for assistance with X-ray diffraction data collection and processing. We thank Greg Hura and Kathryn Burnett for assistance with SAXS data collection and processing. X-ray diffraction data collection and processing were conducted at the Northeastern Collaborative Access Team beamlines, which are funded by the National Institute of General Medical Sciences from the National

821 Institutes of Health (P30 GM124165). The Eiger 16M
822 detector on 24-ID-E is funded by a NIH-ORIP HEI grant
823 (S10OD021527). This research used resources of the
824 Advanced Photon Source, a U.S. Department of Energy
825 (DOE) Office of Science User Facility operated for the DOE
826 Office of Science by Argonne National Laboratory under
827 Contract No. DE-AC02-06CH11357. SAXS experiments were
828 conducted at the Advanced Light Source (ALS), a national
829 user facility operated by Lawrence Berkeley National
830 Laboratory on behalf of the Department of Energy, Office of
831 Basic Energy Sciences, through the Integrated Diffraction
832 Analysis Technologies (IDAT) program, supported by DOE
833 Office of Biological and Environmental Research. Additional
834 support comes from the National Institute of Health project
835 ALS-ENABLE (P30 GM124169) and a High-End Instrumentation
836 Grant S10OD018483.

837 ■ ABBREVIATIONS

838 FMO, flavin-dependent monooxygenase; NHP, N-hydroxyputrescine;
839 NMO, N-hydroxylating monooxygenase; NRPS, nonribosomal peptide synthase;
840 FMOs, flavin monooxygenases; SAXS, small-angle X-ray scattering

842 ■ REFERENCES

843 (1) Lee, C. R.; Lee, J. H.; Park, M.; Park, K. S.; Bae, I. K.; Kim, Y. B.;
844 Cha, C. J.; Jeong, B. C.; Lee, S. H. Biology of *Acinetobacter*
845 *baumannii*: Pathogenesis, Antibiotic Resistance Mechanisms, and
846 Prospective Treatment Options. *Front. Cell. Infect. Microbiol.* **2017**, *7*,
847 55.
848 (2) Vincent, J. L.; Rello, J.; Marshall, J.; Silva, E.; Anzueto, A.;
849 Martin, C. D.; Moreno, R.; Lipman, J.; Gomersall, C.; Sakr, Y.;
850 Reinhart, K.; Investigators, E. I. G. O. International study of the
851 prevalence and outcomes of infection in intensive care units. *JAMA*
852 **2009**, *302* (21), 2323–9.
853 (3) Peleg, A. Y.; Seifert, H.; Paterson, D. L. *Acinetobacter*
854 *baumannii*: emergence of a successful pathogen. *Clin Microbiol Rev.*
855 **2008**, *21* (3), 538–82.
856 (4) Vrancianu, C. O.; Gheorghe, I.; Czobor, I. B.; Chifiriuc, M. C.
857 Antibiotic Resistance Profiles, Molecular Mechanisms and Innovative
858 Treatment Strategies of *Acinetobacter baumannii*. *Microorganisms*
859 **2020**, *8* (6), 935.
860 (5) Dijkshoorn, L.; Nemeč, A.; Seifert, H. An increasing threat in
861 hospitals: multidrug-resistant *Acinetobacter baumannii*. *Nat. Rev.*
862 *Microbiol.* **2007**, *5* (12), 939–51.
863 (6) Fischbach, M. A.; Lin, H.; Liu, D. R.; Walsh, C. T. How
864 pathogenic bacteria evade mammalian sabotage in the battle for iron.
865 *Nat. Chem. Biol.* **2006**, *2* (3), 132–8.
866 (7) Yamamoto, S.; Okujo, N.; Sakakibara, Y. Isolation and structure
867 elucidation of acinetobactin, a novel siderophore from *Acinetobacter*
868 *baumannii*. *Arch. Microbiol.* **1994**, *162* (4), 249–54.
869 (8) Penwell, W. F.; DeGrace, N.; Tentarelli, S.; Gauthier, L.; Gilbert,
870 C. M.; Arivett, B. A.; Miller, A. A.; Durand-Reville, T. F.; Joubran, C.;
871 Actis, L. A. Discovery and Characterization of New Hydroxamate
872 Siderophores, Baumannoferrin A and B, produced by *Acinetobacter*
873 *baumannii*. *Chembiochem* **2015**, *16* (13), 1896–1904.
874 (9) Proschak, A.; Lubuta, P.; Grun, P.; Lohr, F.; Wilharm, G.; De
875 Berardinis, V.; Bode, H. B. Structure and biosynthesis of fimsbactins
876 A-F, siderophores from *Acinetobacter baumannii* and *Acinetobacter*
877 *baylyi*. *Chembiochem* **2013**, *14* (5), 633–8.
878 (10) Brender, J. R.; Dertouzos, J.; Ballou, D. P.; Massey, V.; Palfey,
879 B. A.; Entsch, B.; Steel, D. G.; Gafni, A. Conformational dynamics of
880 the isoalloxazine in substrate-free p-hydroxybenzoate hydroxylase:
881 single-molecule studies. *J. Am. Chem. Soc.* **2005**, *127* (51), 18171–8.
882 (11) Eijkelkamp, B. A.; Hassan, K. A.; Paulsen, I. T.; Brown, M. H.
883 Investigation of the human pathogen *Acinetobacter baumannii* under
884 iron limiting conditions. *BMC Genomics* **2011**, *12*, 126.

(12) D'Onofrio, A.; Crawford, J. M.; Stewart, E. J.; Witt, K.; Gavrish, 885
E.; Epstein, S.; Clardy, J.; Lewis, K. Siderophores from neighboring 886
organisms promote the growth of uncultured bacteria. *Chem. Biol.* 887
2010, *17* (3), 254–64. 888

(13) McRose, D. L.; Seyedsayamdost, M. R.; Morel, F. M. M. 889
Multiple siderophores: bug or feature? *J. Biol. Inorg. Chem.* **2018**, *23* 890
(7), 983–993. 891

(14) Bohac, T. J.; Fang, L.; Giblin, D. E.; Wenczewicz, T. A. 892
Fimsbactin and Acinetobactin Compete for the Periplasmic Side- 893
rophore Binding Protein BauB in Pathogenic *Acinetobacter* 894
baumannii. *ACS Chem. Biol.* **2019**, *14* (4), 674–687. 895

(15) Sheldon, J. R.; Skaar, E. P. *Acinetobacter baumannii* can use 896
multiple siderophores for iron acquisition, but only acinetobactin is 897
required for virulence. *PLoS Pathog.* **2020**, *16* (10), No. e1008995. 898

(16) Mugge, C.; Heine, T.; Baraibar, A. G.; van Berkel, W. J. H.; 899
Paul, C. E.; Tischler, D. Flavin-dependent N-hydroxylating enzymes: 900
distribution and application. *Appl. Microbiol. Biotechnol.* **2020**, *104* 901
(15), 6481–6499. 902

(17) Huijbers, M. M.; Montersino, S.; Westphal, A. H.; Tischler, D.; 903
van Berkel, W. J. Flavin dependent monooxygenases. *Arch. Biochem.* 904
Biophys. **2014**, *544*, 2–17. 905

(18) Chapman, S. K.; Reid, G. A. *Flavoprotein Protocols*; Humana 906
Press, 1999; Vol. 131, pp 5–7. 907

(19) Oppenheimer, M.; Poulin, M. B.; Lowary, T. L.; Helm, R. F.; 908
Sobrado, P. Characterization of recombinant UDP-galactopyranose 909
mutase from *Aspergillus fumigatus*. *Arch. Biochem. Biophys.* **2010**, *502* 910
(1), 31–8. 911

(20) Chocklett, S. W.; Sobrado, P. *Aspergillus fumigatus* SidA is a 912
highly specific ornithine hydroxylase with bound flavin cofactor. 913
Biochemistry **2010**, *49* (31), 6777–83. 914

(21) Csáky, T. Z.; Hassel, O.; Rosenberg, T.; Lång, S.; Turunen, E.; 915
Tuhkanen, A. On the Estimation of Bound Hydroxylamine in 916
Biological Materials. *Acta Chem. Scand.* **1948**, *2* (2), 450–454. 917

(22) Robinson, R. M.; Rodriguez, P. J.; Sobrado, P. Mechanistic 918
studies on the flavin-dependent N(6)-lysine monooxygenase MbsG 919
reveal an unusual control for catalysis. *Arch. Biochem. Biophys.* **2014**, 920
550–551, 58–66. 921

(23) Valentino, H.; Sobrado, P. Performing anaerobic stopped-flow 922
spectrophotometry inside of an anaerobic chamber. *Methods Enzymol* 923
2019, *620*, 51–88. 924

(24) Kabsch, W. XDS. *Acta Crystallogr. D Biol. Crystallogr.* **2010**, *66* 925
(2), 125–132. 926

(25) Evans, P. R.; Murshudov, G. N. How good are my data and 927
what is the resolution? *Acta Crystallogr. D Biol. Crystallogr.* **2013**, *69* 928
(7), 1204–1214. 929

(26) Matthews, B. W. Solvent content of protein crystals. *J. Mol. Biol.* 930
1968, *33* (2), 491–7. 931

(27) Giddings, L. A.; Lountos, G. T.; Kim, K. W.; Brockley, M.; 932
Needle, D.; Cherry, S.; Tropea, J. E.; Waugh, D. S. Characterization of 933
a broadly specific cadaverine N-hydroxylase involved in desferriox- 934
amine B biosynthesis in *Streptomyces svaceus*. *PLoS One* **2021**, *16* 935
(3), No. e0248385. 936

(28) Leferink, N. G.; Heuts, D. P.; Fraaije, M. W.; van Berkel, W. J. 937
The growing VAO flavoprotein family. *Archives of biochemistry and* 938
biophysics **2008**, *474* (2), 292–301. 939

(29) Adams, P. D.; Afonine, P. V.; Bunkoczi, G.; Chen, V. B.; Echols, 940
N.; Headd, J. J.; Hung, L. W.; Jain, S.; Kapral, G. J.; Grosse Kunstleve, 941
R. W.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R. D.; Read, R. J.; 942
Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P. H. 943
The Phenix software for automated determination of macromolecular 944
structures. *Methods* **2011**, *55* (1), 94–106. 945

(30) McCoy, A. J. Solving structures of protein complexes by 946
molecular replacement with Phaser. *Acta Crystallogr. D Biol.* 947
Crystallogr. **2007**, *63* (1), 32–41. 948

(31) Emsley, P.; Cowtan, K. Coot: model-building tools for 949
molecular graphics. *Acta Crystallogr. D Biol. Crystallogr.* **2004**, *60* 950
(12), 2126–2132. 951

(32) Liebschner, D.; Afonine, P. V.; Moriarty, N. W.; Poon, B. K.; 952
Sobolev, O. V.; Terwilliger, T. C.; Adams, P. D. Polder maps: 953

- 954 improving OMIT maps by excluding bulk solvent. *Acta Crystallogr. D*
955 *Struct. Biol.* **2017**, *73* (2), 148–157.
- 956 (33) Adams, P. D.; Afonine, P. V.; Bunkoczi, G.; Chen, V. B.; Davis,
957 I. W.; Echols, N.; Headd, J. J.; Hung, L. W.; Kapral, G. J.; Grosse-
958 Kunstleve, R. W.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R.; Read, R.
959 J.; Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P.
960 H. PHENIX: a comprehensive Python-based system for macro-
961 molecular structure solution. *Acta Crystallogr. D Biol. Crystallogr.*
962 **2010**, *66* (2), 213–221.
- 963 (34) Gore, S.; Sanz Garcia, E.; Hendrickx, P. M. S.; Gutmanas, A.;
964 Westbrook, J. D.; Yang, H.; Feng, Z.; Baskaran, K.; Berrisford, J. M.;
965 Hudson, B. P.; Ikegawa, Y.; Kobayashi, N.; Lawson, C. L.; Mading, S.;
966 Mak, L.; Mukhopadhyay, A.; Oldfield, T. J.; Patwardhan, A.; Peisach,
967 E.; Sahni, G.; Sekharan, M. R.; Sen, S.; Shao, C.; Smart, O. S.; Ulrich,
968 E. L.; Yamashita, R.; Quesada, M.; Young, J. Y.; Nakamura, H.;
969 Markley, J. L.; Berman, H. M.; Burley, S. K.; Velankar, S.; Kleywegt,
970 G. J. Validation of Structures in the Protein Data Bank. *Structure*
971 **2017**, *25* (12), 1916–1927.
- 972 (35) Dyer, K. N.; Hammel, M.; Rambo, R. P.; Tsutakawa, S. E.;
973 Rodic, I.; Classen, S.; Tainer, J. A.; Hura, G. L. High-throughput
974 SAXS for the characterization of biomolecules in solution: a practical
975 approach. *Methods Mol. Biol., Clifton, NJ* **2014**, *1091*, 245–58.
- 976 (36) Konarev, P. V.; Volkov, V. V.; Sokolova, A. V.; Koch, M. H. J.;
977 Svergun, D. I. PRIMUS: a Windows PC-based system for small-angle
978 scattering data analysis. *J. Appl. Crystallogr.* **2003**, *36* (5), 1277–1282.
- 979 (37) Piiadov, V.; Ares de Araujo, E.; Oliveira Neto, M.; Craievich, A.
980 F.; Polikarpov, I. SAXSMoW 2.0: Online calculator of the molecular
981 weight of proteins in dilute solution from experimental SAXS data
982 measured on a relative scale. *Protein Sci.* **2019**, *28* (2), 454–463.
- 983 (38) Schneidman-Duhovny, D.; Hammel, M.; Sali, A. FoXS: a web
984 server for rapid computation and fitting of SAXS profiles. *Nucleic*
985 *Acids Res.* **2010**, *38*, W540–W544.
- 986 (39) Kikhney, A. G.; Borges, C. R.; Molodenskiy, D. S.; Jeffries, C.
987 M.; Svergun, D. I. SASBDB: Towards an automatically curated and
988 validated repository for biological scattering data. *Protein Sci.* **2020**, *29*
989 (1), 66–75.
- 990 (40) Chaiyen, P.; Fraaije, M. W.; Mattevi, A. The enigmatic reaction
991 of flavins with oxygen. *Trends in biochemical sciences* **2012**, *37* (9),
992 373–80.
- 993 (41) Han, A.; Robinson, R. M.; Badiayan, S.; Ellerbrock, J.; Sobrado,
994 P. Tryptophan-47 in the active site of *Methylophaga* sp. strain SK1
995 flavin-monooxygenase is important for hydride transfer. *Arch.*
996 *Biochem. Biophys.* **2013**, *532* (1), 46–53.
- 997 (42) van Berkel, W. J.; Kamerbeek, N. M.; Fraaije, M. W.
998 Flavoprotein monooxygenases, a diverse class of oxidative biocatalysts.
999 *Journal of biotechnology* **2006**, *124* (4), 670–89.
- 1000 (43) Krissinel, E.; Henrick, K. Secondary-structure matching (SSM),
1001 a new tool for fast protein structure alignment in three dimensions.
1002 *Acta Crystallogr. D Biol. Crystallogr.* **2004**, *60* (12), 2256–68.
- 1003 (44) Krissinel, E.; Henrick, K. Inference of macromolecular
1004 assemblies from crystalline state. *J. Mol. Biol.* **2007**, *372* (3), 774–97.
- 1005 (45) Meneely, K. M.; Lamb, A. L. Biochemical characterization of a
1006 flavin adenine dinucleotide-dependent monooxygenase, ornithine
1007 hydroxylase from *Pseudomonas aeruginosa*, suggests a novel reaction
1008 mechanism. *Biochemistry* **2007**, *46* (42), 11930–7.
- 1009 (46) Hajizadeh, N. R.; Franke, D.; Jeffries, C. M.; Svergun, D. I.
1010 Consensus Bayesian assessment of protein molecular mass from
1011 solution X-ray scattering data. *Sci. Rep.* **2018**, *8* (1), 7204.
- 1012 (47) Schneidman-Duhovny, D.; Kim, S. J.; Sali, A. Integrative
1013 structural modeling with small angle X-ray scattering profiles. *BMC*
1014 *Struc. Biol.* **2012**, *12*, 17.
- 1015 (48) Guttman, M.; Weinkam, P.; Sali, A.; Lee, K. K. All-atom
1016 ensemble modeling to analyze small-angle x-ray scattering of
1017 glycosylated proteins. *Structure* **2013**, *21* (3), 321–31.
- 1018 (49) Campbell, A. C.; Robinson, R.; Mena-Aguilar, D.; Sobrado, P.;
1019 Tanner, J. J. Structural Determinants of Flavin Dynamics in a Class B
1020 Monooxygenase. *Biochemistry* **2020**, *59* (48), 4609–4616.
- (50) Bottoms, C. A.; Smith, P. E.; Tanner, J. J. A structurally
1021 conserved water molecule in Rossmann dinucleotide-binding
1022 domains. *Protein Soc.* **2002**, *11* (9), 2125–37.
- (51) Abdelwahab, H.; Robinson, R.; Rodriguez, P.; Adly, C.; El-
1023 Sohaimy, S.; Sobrado, P. Identification of structural determinants of
1024 NAD(P)H selectivity and lysine binding in lysine N(6)-monoox-
1025 ygenase. *Arch. Biochem. Biophys.* **2016**, *606*, 180–8.
- (52) Binda, C.; Robinson, R. M.; Martin Del Campo, J. S.; Keul, N.
1028 D.; Rodriguez, P. J.; Robinson, H. H.; Mattevi, A.; Sobrado, P. An
1029 Unprecedented NADPH Domain Conformation in Lysine Mono-
1030 oxygenase NbtG Provides Insights into Uncoupling of Oxygen
1031 Consumption from Substrate Hydroxylation. *J. Biol. Chem.* **2015**, *290*
1032 (20), 12676–88.
- (53) Valentino, H.; Campbell, A. C.; Schuermann, J. P.; Sultana, N.;
1034 Nam, H. G.; LeBlanc, S.; Tanner, J. J.; Sobrado, P. Structure and
1035 function of a flavin-dependent S-monooxygenase from garlic (*Allium*
1036 *sativum*). *J. Biol. Chem.* **2020**, *295* (32), 11042–11055.
- (54) Shirey, C.; Badiayan, S.; Sobrado, P. Role of Ser-257 in the
1038 sliding mechanism of NAD(P)H in the reaction catalyzed by the
1039 *Aspergillus fumigatus* flavin-dependent ornithine N5-monooxygenase
1040 SidA. *J. Biol. Chem.* **2013**, *288* (45), 32440–8.
- (55) Sobrado, P. Flavin-Dependent N-Hydroxylating monooxyge-
1042 nases in Bacterial and Fungi Siderophore Biosynthesis. In *Flavins and*
1043 *Flavoproteins 2011*; Miller, S., Hille, R., Palfey, B., Eds.; Lulu.com,
1044 2013; pp 265–276.
- (56) Robinson, R.; Badiayan, S.; Sobrado, P. C4a-hydroperoxyflavin
1046 formation in N-hydroxylating flavin monooxygenases is mediated by
1047 the 2'-OH of the nicotinamide ribose of NAD(+). *Biochemistry*
1048 **2013**, *52* (51), 9089–91.
- (57) Ruangchan, N.; Tongsook, C.; Sucharitakul, J.; Chaiyen, P. pH-
1050 dependent Studies Reveal an Efficient Hydroxylation Mechanism of
1051 the Oxygenase Component of p-Hydroxyphenylacetate 3-Hydrox-
1052 ylase. *J. Biol. Chem.* **2011**, *286* (1), 223–233.
- (58) Pimviriyakul, P.; Thotsaporn, K.; Sucharitakul, J.; Chaiyen, P.
1054 Kinetic Mechanism of the Dechlorinating Flavin-Dependent Mono-
1055 oxygenase HadA. *J. Biol. Chem.* **2017**, *292* (12), 4818–4832.
- (59) Alfieri, A.; Malito, E.; Orru, R.; Fraaije, M. W.; Mattevi, A.
1057 Revealing the moonlighting role of NADP in the structure of a flavin-
1058 containing monooxygenase. *Proc. Natl. Acad. Sci. U.S.A.* **2008**, *105*
1059 (18), 6572–7.
- (60) Entsch, B.; van Berkel, W. J. Structure and mechanism of para-
1061 hydroxybenzoate hydroxylase. *FASEB J.* **1995**, *9* (7), 476–83.
- (61) Olucha, J.; Lamb, A. L. Mechanistic and structural studies of
1063 the N-hydroxylating flavoprotein monooxygenases. *Bioorganic chem-*
1064 *istry* **2011**, *39* (5–6), 171–7.
- (62) Franceschini, S.; Fedkenheuer, M.; Vogelaar, N. J.; Robinson,
1066 H. H.; Sobrado, P.; Mattevi, A. Structural insight into the mechanism
1067 of oxygen activation and substrate selectivity of flavin-dependent N-
1068 hydroxylating monooxygenases. *Biochemistry* **2012**, *51* (36), 7043–5.
- (63) Romero, E.; Fedkenheuer, M.; Chocklett, S. W.; Qi, J.;
1070 Oppenheimer, M.; Sobrado, P. Dual role of NAD(P)H in the reaction
1071 of a flavin dependent N-hydroxylating monooxygenase. *Biochim.*
1072 *Biophys. Acta* **2012**, *1824* (6), 850–7.
- (64) Campbell, A. C.; Stiers, K. M.; Martin del Campo, J. S.; Mehra-
1074 Chaudhary, R.; Sobrado, P.; Tanner, J. J. Trapping conformational
1075 states of a flavin-dependent N-monooxygenase in crystallo reveals
1076 protein and flavin dynamics. *J. Biol. Chem.* **2020**, *295* (38), 13239–49.